Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
(NY:
ANRO
)
12.70
+0.20 (+1.60%)
Streaming Delayed Price
Updated: 2:45 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about ANRO
Alto Neuroscience Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 13, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Alto Neuroscience Receives Funding Award from Wellcome Trust to Accelerate Development of ALTO-100 in Bipolar Depression Leveraging Precision Psychiatry Approach
July 25, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Alto Neuroscience Announces Enrollment Completion in Phase 2b Study of ALTO-100 in Major Depressive Disorder
July 16, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia
June 20, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year® 2024 Bay Area Award Winner
June 18, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Alto Neuroscience to Present at the Jefferies Global Healthcare Conference
May 29, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer
May 21, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 14, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences
May 09, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
April 23, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder
April 03, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights
March 21, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors
March 11, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Alto Neuroscience to Participate in Upcoming Investor Conferences
March 07, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Alto Neuroscience to Present at the TD Cowen 44th Annual Healthcare Conference
February 27, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Alto Neuroscience Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
February 06, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.